Patient characteristics and outcome
| Pt no. . | Age, y . | Sex . | Diagnosis . | Disease stage . | Conditioning . | CD34+ infused, × 105/kg . | Cells infused, × 107/kg . | HLA-I match . | CMV serology R/D . | Acute GVHD . | Chronic GVHD . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 47 | F | AML | First CR | CY + TBI | 2.75 | 3.4 | 4/6 | Pos/neg | No | No | Alive |
| 2 | 44 | M | AML | First CR | CY + TBI | 1.7 | 2.0 | 4/6 | Pos/neg | Grade I | No | Alive |
| 3 | 46 | F | AML | First CR | CY + TBI | 2.7 | 3.87 | 4/6 | Neg/neg | Grade I | Grade I | Relapsed, dead after 29 mo after UCBT |
| 4 | 35 | M | MDS | NA | CY + TBI | 1.0 | 2.19 | 4/6 | Pos/pos | No | No | Alive |
| 5 | 34 | F | AML | Second CR | CY + TBI | 1.1 | 2.32 | 4/6 | Pos/neg | Grade II | No | Alive |
| 6 | 38 | M | AML | Second CR | CY + TBI | 1.16 | 3.2 | 4/6 | Pos/neg | no | No | Alive |
| 7 | 39 | M | AML | Disease present | CY + TBI | 3.4 | 3.56 | 4/6 | Pos/pos | no | No | Relapsed, dead after 6 mo after UCBT |
| 8 | 38 | F | AML | First CR | CY + TBI | 4.1 | 5.5 | 5/6 | Pos/neg | Grade I | Grade I | Alive |
| 9 | 21 | M | AML | First CR | CY + TBI | 2.16 | 2.89 | 4/6 | Neg/NA | No | Grade I | Alive |
| 10 | 50 | F | AML | Second CR | CY + TBI | 0.99 | 3.9 | 4/6 | Pos/neg | Grade I | Grade I | Alive |
| 11 | 63 | M | CML | RF | THIO TREO FLU | 0.68 | 2.13 | 4/6 | Pos/neg | Grade I | Grade I | Relapsed, dead after 23 mo after UCBT |
| 12 | 41 | M | AML | Disease present | CY + TBI | 0.77 | 3.33 | 4/6 | Pos/neg | Grade I | Grade I | Alive |
| 13 | 39 | F | AML | RF | CY + TBI | 1.1 | 3.9 | 4/6 | Pos/pos | No | No | Alive |
| 14 | 33 | F | AML | RF | CY + TBI | 1.89 | 3.43 | 4/6 | Neg/NA | Grade I | No | Alive |
| 15 | 35 | M | ALL | RF | CY + TBI | 1.04 | 3.12 | 4/6 | Pos/neg | No | No | Relapsed, dead before 3 mo after UCBT |
| 16 | 46 | M | AML | First CR | CY + TBI | 1.26 | 4.08 | 4/6 | Pos/neg | Grade II | Grade II | Relapsed, dead before 3 mo after UCBT |
| 17 | 60 | F | ALL | Second CR | FLU + TBI | 0.83 | 3.02 | 4/6 | Pos/neg | Grade I | NA | Relapsed, dead before 3 mo after UCBT |
| 18 | 27 | M | AML | RF | CY + TBI | 1.46 | 2.66 | 4/6 | Neg/pos | Grade I | Grade III | GVHD, dead before 3 mo after UCBT |
| Pt no. . | Age, y . | Sex . | Diagnosis . | Disease stage . | Conditioning . | CD34+ infused, × 105/kg . | Cells infused, × 107/kg . | HLA-I match . | CMV serology R/D . | Acute GVHD . | Chronic GVHD . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 47 | F | AML | First CR | CY + TBI | 2.75 | 3.4 | 4/6 | Pos/neg | No | No | Alive |
| 2 | 44 | M | AML | First CR | CY + TBI | 1.7 | 2.0 | 4/6 | Pos/neg | Grade I | No | Alive |
| 3 | 46 | F | AML | First CR | CY + TBI | 2.7 | 3.87 | 4/6 | Neg/neg | Grade I | Grade I | Relapsed, dead after 29 mo after UCBT |
| 4 | 35 | M | MDS | NA | CY + TBI | 1.0 | 2.19 | 4/6 | Pos/pos | No | No | Alive |
| 5 | 34 | F | AML | Second CR | CY + TBI | 1.1 | 2.32 | 4/6 | Pos/neg | Grade II | No | Alive |
| 6 | 38 | M | AML | Second CR | CY + TBI | 1.16 | 3.2 | 4/6 | Pos/neg | no | No | Alive |
| 7 | 39 | M | AML | Disease present | CY + TBI | 3.4 | 3.56 | 4/6 | Pos/pos | no | No | Relapsed, dead after 6 mo after UCBT |
| 8 | 38 | F | AML | First CR | CY + TBI | 4.1 | 5.5 | 5/6 | Pos/neg | Grade I | Grade I | Alive |
| 9 | 21 | M | AML | First CR | CY + TBI | 2.16 | 2.89 | 4/6 | Neg/NA | No | Grade I | Alive |
| 10 | 50 | F | AML | Second CR | CY + TBI | 0.99 | 3.9 | 4/6 | Pos/neg | Grade I | Grade I | Alive |
| 11 | 63 | M | CML | RF | THIO TREO FLU | 0.68 | 2.13 | 4/6 | Pos/neg | Grade I | Grade I | Relapsed, dead after 23 mo after UCBT |
| 12 | 41 | M | AML | Disease present | CY + TBI | 0.77 | 3.33 | 4/6 | Pos/neg | Grade I | Grade I | Alive |
| 13 | 39 | F | AML | RF | CY + TBI | 1.1 | 3.9 | 4/6 | Pos/pos | No | No | Alive |
| 14 | 33 | F | AML | RF | CY + TBI | 1.89 | 3.43 | 4/6 | Neg/NA | Grade I | No | Alive |
| 15 | 35 | M | ALL | RF | CY + TBI | 1.04 | 3.12 | 4/6 | Pos/neg | No | No | Relapsed, dead before 3 mo after UCBT |
| 16 | 46 | M | AML | First CR | CY + TBI | 1.26 | 4.08 | 4/6 | Pos/neg | Grade II | Grade II | Relapsed, dead before 3 mo after UCBT |
| 17 | 60 | F | ALL | Second CR | FLU + TBI | 0.83 | 3.02 | 4/6 | Pos/neg | Grade I | NA | Relapsed, dead before 3 mo after UCBT |
| 18 | 27 | M | AML | RF | CY + TBI | 1.46 | 2.66 | 4/6 | Neg/pos | Grade I | Grade III | GVHD, dead before 3 mo after UCBT |
R/D indicates recipient/donor; AML, acute myeloid leukemia; CR, complete remission; CY, cyclophosphamide; TBI, total body irradiation; UCBT, umbilical CB transplantation; MDS, myelodysplastic syndrome; NA, not available; CML, chronic myeloid leukemia; RF, refractory; THIO, thiotepa; TREO, treosulfan; FLU, fludarabine; and ALL, acute lymphocytic leukemia.